#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17516	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2023	842.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1657	1657	T	1017	T,C	709,221	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17516	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2023	842.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1391	1391	C	1078	C	977	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17516	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2023	842.0	0	HET	.	.	.	C1525T	.	1525	1525	C	1732	1732	C	745	C,T	509,184	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31214	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3642	837.5	0	.	n	.	0	T695C	SNP	695	695	T	984	984	C	1206	C	1119	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31214	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3642	837.5	0	.	n	.	0	A1638G	SNP	1638	1638	A	1927	1927	G	819	G	753	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31214	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3642	837.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2260	2260	C	939	C,T,G	860,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31214	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3642	837.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2334	2334	A	1060	A,G	965,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31214	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3642	837.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	2886	2886	C	1087	C	956	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1216	folP	855	855	100.0	folP.l15.c4.ctg.1	1688	69.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1119	1121	AGC	108;112;113	A;G;C	102;106;106	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3380	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3523	92.9	1	SNP	p	S91F	1	.	.	271	273	TTC	710	712	TTC	126;126;125	T;T;C	117;118;118	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3380	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3523	92.9	1	SNP	p	D95G	1	.	.	283	285	GGC	722	724	GGC	141;141;140	G;G;C	132;133;133	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3380	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3523	92.9	1	SNP	p	G95N	0	.	.	283	285	GGC	722	724	GGC	141;141;140	G;G;C	132;133;133	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	920	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1385	63.8	1	SNP	p	G45D	0	.	.	133	135	GGC	646	648	GGC	124;126;123	G;G;C	114;116;115	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	724	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1222	57.6	0	.	n	.	0	A197.	DEL	197	197	A	768	768	A	150	A	142	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3038	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3039	96.7	1	SNP	p	D86N	0	.	.	256	258	GAC	568	570	GAC	155;154;153	G;A;C	151;149;150	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3038	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3039	96.7	1	SNP	p	S87R	1	.	.	259	261	CGT	571	573	CGT	153;154;153	C;G;T	150;150;149	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3038	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3039	96.7	1	SNP	p	R87I	0	.	.	259	261	CGT	571	573	CGT	153;154;153	C;G;T	150;150;149	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3038	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3039	96.7	1	SNP	p	R87W	0	.	.	259	261	CGT	571	573	CGT	153;154;153	C;G;T	150;150;149	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	3038	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3039	96.7	1	SNP	p	S88P	0	.	.	262	264	TCC	574	576	TCC	153;152;152	T;C;C	149;149;149	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2814	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2898	93.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1673	1675	GGC	81;80;80	G;G;C	79;78;77	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	A311V	0	.	.	931	933	GCC	1352	1354	GCC	219;220;218	G;C;C	188;190;187	penA.10.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	I312M	1	.	.	934	936	ATG	1355	1357	ATG	203;199;200	A;T;G	176;175;175	penA.10.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	T316P	0	.	.	946	948	ACC	1367	1369	ACC	219;218;212	A;C;C	188;193;191	penA.10.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	V316T	1	.	.	946	948	ACC	1367	1369	ACC	219;218;212	A;C;C	188;193;191	penA.10.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1868	1870	ACC	151;153;152	A;C;C	137;142;142	penA.10.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1922	1924	GCG	121;118;122	G;C;G	116;114;115	penA.10.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1922	1924	GCG	121;118;122	G;C;G	116;114;115	penA.10.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2045	2047	GGT	112;115;115	G;G;T	110;114;114	penA.10.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2054	2056	AGC	112;113;114	A;G;C	110;110;111	penA.10.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.10.001	penA.10.001	1	1	27	3290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2566	125.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2072	2074	CCG	110;115;116	C;C;G	106;111;111	penA.10.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4844	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	2838	165.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1407	1409	CCG	73;74;74	C;C;G	69;71;67	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1566	porA	1146	1146	99.91	porA.l15.c17.ctg.1	1781	85.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	546	546	C	97	C	81	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	A196V	NONSYN	586	588	GCC	950	952	GTC	240;237;237	G;T;C	216;208;215	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1121	1123	CAA	176;174;176	CAAAA,CAAAAA;A;A	164,1;168;168	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	.	INDELS	760	761	AC	1125	1128	ATCA	181;180;181;183	A;T;C;A	174;173;175;177	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	.	MULTIPLE	764	765	AC	1133	1135	GTG	180;162;164	G;T,G;G	172;155,1;159	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1139	1141	GAT	170;170;168	G;A;T	162;161;159	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	A270V	NONSYN	808	810	GCG	1178	1180	GTA	246;244;247	G;T;A	212;210;214	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	L277V	NONSYN	829	831	TTA	1199	1201	GTA	228;226;236	G;T;A	198;198;205	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	S290T	NONSYN	868	870	TCT	1238	1240	ACT	217;228;228	A;C,T;T	199;210,1;211	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	H292D	NONSYN	874	876	CAT	1244	1246	GAT	227;221;217	G;A;T	212;207;204	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	0	.	p	.	0	Y296H	NONSYN	886	888	TAC	1256	1258	CAC	197;189;194	C;A;C	183;175;179	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	AAG	194;193;192	A;A;G	178;177;175	porB1b.WHO_X_02194c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	1	SNP	p	D121N	0	.	.	361	363	GAC	725	727	GAC	193;191;194	G;A;C	177;173;174	porB1b.WHO_X_02194c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2178	porB1b	1041	1041	98.28	porB1b.l15.c4.ctg.1	1672	127.5	1	SNP	p	A121D	1	.	.	361	363	GAC	725	727	GAC	193;191;194	G;A;C	177;173;174	porB1b.WHO_X_02194c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	7868	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4509	169.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1731	1733	CAT	195;196;196	C;A;T	184;184;184	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	714	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1240	56.7	1	SNP	p	V57M	1	.	.	169	171	ATG	683	685	ATG	138;136;140	A;T;G	130;127;130	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
